0001437749-26-012182
SEC filingImmuCell Corporation announced board changes effective April 15, 2026, with retirements of three directors and appointments of two new independent directors with animal health expertise, transitioning to a 7-person board with six independents.
The board refresh at ImmuCell strengthens governance with a majority independent structure of six independents plus the CEO, reducing from prior size amid retirements. New appointees bring deep sector expertise: Dr. Guillemette's 30+ years in animal health executive roles at firms like Elanco and Bayer, including P&L and strategy, positions him to lead the new Strategy & Technology Committee focused on innovation. Dr. DiMarco's 40 years in biologics, notably 21 years at IDEXX in R&D and manufacturing, supports yield improvements and product expansion for First Defense®. Retiring directors' long service is acknowledged, with Brigham's 25+ year CEO tenure and Brockmann's ongoing VP role ensuring continuity. This signals strategic focus on innovation-driven growth in calf health products.